Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial
EuroIntervention · 2025
DOI: 10.4244/eij-d-24-00973 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2025. Verfasst von Mauro Gitto und 27 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Ticagrelor, Aspirin, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
- Unit of Interventional Cardiology, Mediterranea Cardiocentro, Naples, Italy.
- Cardiovascular Research Foundation, New York, NY, USA.
Zitieren
APA
Gitto, M., Baber, U., Sartori, S., Vogel, B., Angiolillo, D. J., Briguori, C., Cohen, D. J., Collier, T., Dudek, D., Oliva, A., Escaned, J., Feng, Y., Gibson, C. M., Han, Y. L., Di Muro, F. M., Shlofmitz, R. A., Huber, K., Steg, P. G., Sharma, S., …, & Mehran, R. (2025). Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial. EuroIntervention. https://doi.org/10.4244/eij-d-24-00973
Vancouver
Gitto M, Baber U, Sartori S, Vogel B, Angiolillo DJ, Briguori C, et al. Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial. EuroIntervention. 2025. doi:10.4244/eij-d-24-00973
BibTeX
@article{Gitto2025,
author = {Gitto, Mauro and Baber, Usman and Sartori, Samantha and Vogel, Birgit and Angiolillo, Dominick J and Briguori, Carlo and Cohen, David J and Collier, Timothy and Dudek, Dariusz and Oliva, Angelo and Escaned, Javier and Feng, Yihan and Gibson, C Michael and Han, Ya-Ling and Di Muro, Francesca Maria and Shlofmitz, Richard A and Huber, Kurt and Steg, Philippe Gabriel and Sharma, Samin and Sardella, Gennaro and Kastrati, Adnan and Kaul, Upendra and Kornowski, Ran and Kunadian, Vijay and Stefanini, Giulio G and Mehta, Shamir R and Dangas, George and Mehran, Roxana},
title = {Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial},
journal = {EuroIntervention},
year = {2025},
doi = {10.4244/eij-d-24-00973}
}
EUVIMED